By Tina Hesman Saey A large-scale study of proteins in blood and cerebrospinal fluid could pave the way for improved blood tests to diagnose multiple brain diseases — and potential early warning signs of disease risk — researchers report July 15 in several papers in Nature Medicine and Nature Aging. Proteins do much of the work to keep cells and bodies working. Trouble with these building blocks can spell disease; protein misfolding, for instance, links many brain diseases. The results, drawn from samples from 18,645 people, reveal biochemical fingerprints of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, frontotemporal dementia and amyotrophic lateral sclerosis, or ALS. These tests could also help identify disease subtypes and track progression before symptoms emerge. Such well-validated and robust results are “more likely to ultimately translate into something that’s medically actionable,” says Andrew Saykin, director of the Indiana Alzheimer’s Disease Research Center in Indianapolis, which contributed samples to the effort. In one key finding, researchers discovered that individuals carrying a form of the APOE gene called APOE4 — the biggest genetic risk factor for developing Alzheimer’s — share a blood signature regardless of diagnosis. That signature appeared not only in people with Alzheimer’s but also in those with other brain diseases or no neurodegeneration at all, neuroscientist Caitlin Finney and colleagues report in Nature Medicine. The APOE4 protein signature involves proteins that respond to infection and inflammation, hinting at how the variant predisposes carriers to brain diseases. It also suggests that the APOE4 protein may be involved in the early stages of multiple diseases. © Society for Science & the Public 2000–2025.

Keyword: Development of the Brain; Alzheimers
Link ID: 29860 - Posted: 07.16.2025

By Celina Zhao You could be 45 on paper but 60 in your kidneys. Turns out, your organs have birthdays of their own — and how well they’re faring may set the pace for your health, researchers report July 9 in Nature Medicine. Using data from nearly 45,000 people, scientists developed a blood-based test to estimate the biological age of 11 organs, providing a measure of how healthy or worn down each organ is. When a person has an organ substantially “older” than their actual age, disease risks tied to that organ surge. Conversely, extremely youthful brains and immune systems are linked to living longer, the results suggest. “The fact that [the researchers] can create an organ age using proteins — and use it to predict diseases that you would expect to be predicted from that organ — is quite amazing,” says Sarah Harris, a molecular biologist at the University of Edinburgh who was not involved in the study. Aging is far from a uniform process; each organ follows its own clock of decline. One way to track this hidden timeline, previously discovered by Stanford neurology researchers Hamilton Oh and Tony Wyss-Coray, is through the thousands of proteins coursing through our blood. Some unmistakably originate in the liver, while others can be traced to the lungs. Analyzing these proteins can reveal clues about how each organ is holding up. In the new study, the team zeroed in on thousands of patients from the UK Biobank, a long-term database tracking the health of individuals ages 40 to 70 for up to 17 years. By assessing proteins in the blood, the team determined the average protein signature for, say, a 40-year-old liver or 70-year-old arteries. © Society for Science & the Public 2000–2025.

Keyword: Development of the Brain
Link ID: 29859 - Posted: 07.16.2025

Sally Adee Keith Krehbiel lived with Parkinson’s disease for nearly 25 years before agreeing to try a brain implant that might alleviate his symptoms. He had long been reluctant to submit to the surgery. “It was a big move,” he says. But by 2020, his symptoms had become so severe that he grudgingly agreed to go ahead. Deep-brain stimulation involves inserting thin wires through two small holes in the skull into a region of the brain associated with movement. The hope is that by delivering electrical pulses to the region, the implant can normalize aberrant brain activity and reduce symptoms. Since the devices were first approved almost three decades ago, some 200,000 people have had them fitted to help calm the tremors and rigidity caused by Parkinson’s disease. But about 40,000 of those who received devices made after 2020 got them with a special feature that has largely not yet been turned on. The devices can read brain waves and then adapt and tailor the rhythm of their output, in much the same way as a pacemaker monitors and corrects the heart’s electrical rhythms, says Helen Bronte-Stewart, a neurologist at Stanford University in California. Bronte-Stewart received approval to start a clinical trial of this new technology, known as adaptive deep-brain stimulation (aDBS), the same week that Krehbiel was preparing for surgery. He recalls the phone call in which she asked him if he wanted to be her first participant: “I said, ‘Boy, do I!’” Five years on, the results of this 68-person trial, called ADAPT-PD, are under review for publication. Although the exact details are still under wraps, they were convincing enough to earn approval for the technology earlier this year from both US and European regulators. © 2025 Springer Nature Limited

Keyword: Parkinsons
Link ID: 29858 - Posted: 07.16.2025

By Celina Ribeiro Some say it was John Sattler’s own fault. The lead-up to the 1970 rugby league grand final had been tense; the team he led, the South Sydney Rabbitohs, had lost the 1969 final. Here was an opportunity for redemption. The Rabbitohs were not about to let glory slip through their fingers again. Soon after the starting whistle, Sattler went in for a tackle. As he untangled – in a move not uncommon in the sport at the time – he gave the Manly Sea Eagles’ John Bucknall a clip on the ear. Seconds later – just three minutes into the game – the towering second rower returned favour with force: Bucknall’s mighty right arm bore down on Sattler, breaking his jaw in three places and tearing his skin; he would later need eight stitches. When his teammate Bob McCarthy turned to check on him, he saw his captain spurting blood, his jaw hanging low. Forty years later Sattler would recall that moment. One thought raged in his shattered head: “I have never felt pain like this in my life.” But he played on. Tackling heaving muscular players as they advanced. Being tackled in turn, around the head, as he pushed forward. All the while he could feel his jaw in pieces. At half-time the Rabbitohs were leading. In the locker room, Sattler warned his teammates, “Don’t play me out of this grand final.” McCarthy told him, “Mate, you’ve got to go off.” He refused. “I’m staying.” Sattler played the whole game. The remaining 77 minutes. At the end, he gave a speech and ran a lap of honour. The Rabbitohs had won. The back page of the next day’s Sunday Mirror screamed “BROKEN JAW HERO”. © 2025 Guardian News & Media Limited

Keyword: Pain & Touch
Link ID: 29857 - Posted: 07.16.2025

By Shaena Montanari Leafcutter ants’ roles can be reprogrammed by manipulating two neuropeptides, according to a new study. These ants are known for their rigorous division of labor in a caste system, with groups performing roles ranging from cutting leaves to nest defense to tending the fungus that is their food source. Despite physical differences among the ants—the heads of the nest defender ants can be five times the size of the fungal carers’ heads, for instance—it’s still possible to “pharmacologically reprogram them to assume some of the roles that typically other castes assume,” indicating behavioral flexibility, says Daniel Kronauer, professor at Rockefeller University, who was not involved in the work. The researchers induced the behavioral changes by first using RNA sequencing to uncover target neuropeptides and then manipulating neuropeptide levels in the ants. The study was published in June in Cell. The work illustrates the close relationship between neuropeptides and behavior, says Shelley Berger, professor of cell and developmental biology at the University of Pennsylvania and principal investigator of the study. Defender ants are “so big and awkward and clumsy,” she says, but after a certain neuropeptide level is lowered, the ant becomes a “nurse tending to the brood.” The study shows the “importance of neuropeptides as these molecular controllers of incredibly complex” behavioral traits, says Zoe Donaldson, professor of behavioral neuroscience at the University of Colorado Boulder, who was not involved in the study. “I think it’s a really elegant demonstration of just how powerful they are.” Almost all species of ants live in colonies, but leafcutter ants (Atta cephalotes) have a particularly intricate labor division, says study investigator Karl Glastad, assistant professor of biology at the University of Rochester. He and Berger previously explored hormonal controls of social behavior in Florida carpenter ants, which have two worker subtypes, but leafcutter ants are a “really elaborated version” of that species, Glastad says. © 2025 Simons Foundation

Keyword: Hormones & Behavior; Evolution
Link ID: 29856 - Posted: 07.16.2025

Smriti Mallapaty A gene variant known to increase the risk of Alzheimer’s disease also makes people vulnerable to a host of other age-related brain disorders, from Parkinson’s disease to motor neuron disease. The gene variant, a version of apolipoprotein E called APOE ε4, produces a distinct set of proteins that contribute to chronic inflammation, finds an analysis1 using the largest proteomics database for neurodegenerative disease. Neurodegenerative diseases affect more than 57 million people worldwide. Researchers know that people who carry the APOE ε4 variant have an increased risk of developing late-onset Alzheimer’s disease, but studies are beginning to implicate this version, or allele, of APOE in other neurodegenerative diseases. Caitlin Finney and Artur Shvetcov, who study neurodegenerative diseases at the Westmead Institute for Medical Research in Sydney, Australia, and their colleagues wanted to better understand how this genetic risk factor contributes to disease. They took advantage of a newly established proteomics database that allowed them to look beyond individual diseases, says Finney. The Global Neurodegeneration Proteomics Consortium (GNPC) data set2 includes samples from more than 18,600 individuals, mainly of European ancestry, including many with Alzheimer’s, Parkinson’s, a form of motor neuron disease called amyotrophic lateral sclerosis (ALS) and types of dementia, as well as individuals without neurological disorders. The consortia collected around 250 million measurements of proteins found in the blood and cerebrospinal fluid, which surrounds the brain and spinal cord, taken at some two dozen clinics across the United States and Europe. “It’s one of the most powerful databases that we have available for proteomics right now,” says Maryam Shoai, a bioinformatician at University College London. Predicting risk © 2025 Springer Nature Limited

Keyword: Alzheimers; Parkinsons
Link ID: 29855 - Posted: 07.16.2025

By Jan Hoffman Jamie Mains showed up for her checkup so high that there was no point in pretending otherwise. At least she wasn’t shooting fentanyl again; medication was suppressing those cravings. Now it was methamphetamine that manacled her, keeping her from eating, sleeping, thinking straight. Still, she could not stop injecting. “Give me something that’s going to help me with this,” she begged her doctor. “There is nothing,” the doctor replied. Overcoming meth addiction has become one of the biggest challenges of the national drug crisis. Fentanyl deaths have been dropping, in part because of medications that can reverse overdoses and curb the urge to use opioids. But no such prescriptions exist for meth, which works differently on the brain. In recent years, meth, a highly addictive stimulant, has been spreading aggressively across the country, rattling communities and increasingly involved in overdoses. Lacking a medical treatment, a growing number of clinics are trying a startlingly different strategy: To induce patients to stop using meth, they pay them. The approach has been around for decades, but most clinics were uneasy about adopting it because of its bluntly transactional nature. Patients typically come in twice a week for a urine drug screen. If they test negative, they are immediately handed a small reward: a modest store voucher, a prize or debit card cash. The longer they abstain from use, the greater the rewards, with a typical cumulative value of nearly $600. The programs, which usually last three to six months, operate on the principle of positive reinforcement, with incentives intended to encourage repetition of desired behavior — somewhat like a parent who permits a child to stay up late as a reward for good grades. Research shows that the approach, known in addiction treatment as “contingency management,” or CM, produces better outcomes for stimulant addiction than counseling or cognitive behavioral therapy. Follow-up studies of patients a year after they successfully completed programs show that about half remained stimulant-free. © 2025 The New York Times Company

Keyword: Drug Abuse
Link ID: 29854 - Posted: 07.16.2025

Mariana Lenharo A speedy imaging method can map the nerves running from a mouse’s brain and spinal cord to the rest of its body at micrometre-scale resolution, revealing details such as individual fibres travelling from a key nerve to distant organs1. Previous efforts have mapped the network of connections between nerve cells, known as the connectome, in the mouse brain. But tracing the complex paths of nerves through the rest of the body has been challenging. To do so, the creators of the new map used a custom-built microscope to scan exposed tissue, completing the process in just 40 hours. Nerves look blue in the reconstructed view of a genetically engineered mouse (left) whose neurons produce a fluorescent marker. In a separate animal (right), antibodies detail the sympathetic nerves (purple). Credit: M.-Y. Shi et al./Cell (CC-BY-4.0) The method, described today in Cell, is an important technical achievement, says Ann-Shyn Chiang, a neuroscientist at the National Tsing Hua University in Hsinchu, Taiwan, who was not involved with the research. “This work is a major step forward in expanding connectomics beyond the brain,” he says. To prepare a mouse’s body for the scan, researchers treat it with chemicals that make its tissues transparent by removing fat, calcium and other components that block light. This provides a clear view of the nerves, which have been labelled with fluorescent marker proteins. The see-through body is then placed into a device that combines a slicing tool and a microscope that takes 3D images. A piston gradually pushes the mouse towards the slicing blade, 400 micrometres at a time. After each slice, a microscope images the newly exposed surface of the mouse, capturing details up to 600 micrometres deep — roughly the thickness of six sheets of paper — below the surface. The body then advances for the next cut. The cycle repeats around 200 times without pause, to cover the entire body. The images are then combined. © 2025 Springer Nature Limited

Keyword: Brain imaging; Development of the Brain
Link ID: 29853 - Posted: 07.12.2025

By Claudia López Lloreda Neural progenitor cells exist in the adult human hippocampus all the way into old age, a new transcriptomics study published today in Science suggests. The results strengthen the claim that adults can form new neurons, according to the team behind the work. But not everyone is convinced that the study shows progenitors are prevalent enough in adulthood to really matter. “Look, there might be something,” says Juan Arellano, a research scientist in neuroscience at Yale University who was not involved with the study. But the cells seem to be rare, because the team could not identify them without the help of a machine-learning algorithm, he adds. “Are they really so relevant in the circuit?” Although the researchers did not quantify the number of cells in their study, newborn neurons are highly excitatory and plastic, so they might still contribute functionally even if there are few, says study investigator Ionut Dumitru, research specialist in Jonas Frisén’s lab at the Karolinska Institutet. Proliferating neurons in adults were first documented in a 1998 study that used a synthetic nucleoside to track newly synthesized DNA in newborn cells. Subsequent work involving carbon dating, lineage tracing and tissue-staining techniques bolstered the idea that people can continue to produce new neurons after childhood. But other studies that stained for cellular markers of neurogenesis suggest that few neurons are born in adults, and the rate of neurogenesis declines dramatically during the first few years of life. These results led some researchers in the field to question the extent and role of neurogenesis in the adult brain, says Shawn Sorrells, assistant professor of neuroscience at the University of Pittsburgh, who conducted some of these cellular marker studies but was not involved with the new one. © 2025 Simons Foundation

Keyword: Neurogenesis; Development of the Brain
Link ID: 29852 - Posted: 07.12.2025

By Dan Falk I’ve been fascinated by time for as long as I can remember. In my undergraduate physics classes, time always lurked in the background—it was the “t” that the professors sprinkled into their equations—but it was never quite clear what time actually was. Years later, I wrote a book about time, but even with chapters on Newton and Einstein, and a solid dose of philosophy, something was missing. Nautilus Members enjoy an ad-free experience. Log in or Join now . For starters, we know clocks and watches work, but how do we tell time? If you’re watching network TV and a commercial break begins, you know you have time to use the bathroom or perhaps make a sandwich—in fact, you can probably arrange to be back in front of the TV just as the ads are ending. What makes you so good at judging these intervals of time? I figured that Dean Buonomano, being a neuroscientist, might have some of the answers. Buonomano is known for developing the idea that the key mechanism is not a single clock-like structure in the brain but rather networks of neurons working together, known as “neural dynamics.” But as Buonomano sees it, the brain does much more than keep track of time; in fact, it might be said to create it. It’s thanks to our brains that we feel time’s “flow,” even though nothing in physics points to such a flow out there in the world. Perhaps even more crucially, the brain allows us to engage in “mental time travel”—the ability to recall past events and imagine future happenings. This capability, he argues, was essential in shaping humanity’s path from the African savannah to today’s globe-spanning civilization. © 2025 NautilusNext Inc.,

Keyword: Attention
Link ID: 29851 - Posted: 07.12.2025

By Ellen Barry Few practices in mental health are debated more than the long-term use of antidepressant medications, which are prescribed to roughly one in nine adults in the United States, according to data from the Centers for Disease Control and Prevention. A reassessment began in 2019, when two British researchers published a study that found that 56 percent of patients suffered from withdrawal symptoms when they stopped antidepressant medications and that 46 percent of those described their symptoms as severe. The findings made headlines in Britain and had a powerful ripple effect, forcing changes to psychiatric training and prescribing guidelines. And they fed a growing grass-roots movement calling to rein in the prescription of psychotropic drugs that has, in recent months, gained new influence in the United States with the rise of Robert F. Kennedy Jr. as health secretary. A new study, published on Wednesday in the journal JAMA Psychiatry, makes the case that these warnings were overblown. The authors of the new paper found that a week after quitting antidepressants, patients reported symptoms like dizziness, nausea and vertigo, but that they remained, on average, “below the threshold for clinically significant” withdrawal. Dr. Sameer Jauhar, one of the authors, said the new analysis should reassure both patients and prescribers. “The messaging that came out in 2019 was all antidepressants can cause this and this can happen in this proportion of people, and that just doesn’t survive any scientific scrutiny,” said Dr. Jauhar, a professor of psychiatry at Imperial College London. He criticized the earlier study for including data from online surveys as a quantitative measure, for failing to control for the placebo effect, and for failing to distinguish between various types of antidepressants. These methodologies, he said, led to inflated estimates of withdrawal. © 2025 The New York Times Company

Keyword: Depression
Link ID: 29850 - Posted: 07.12.2025

Sydney Lupkin Jerry Abrams, a 64-year-old marketing strategist in Minneapolis, used to run marathons. But two decades of degenerative spine disease have left him unable to run — and he's grieving. For Abrams, losing running felt like "the loss of a loved one – that friend who's been with you every day you needed him. "You know, having that taken away from you because of pain is the hardest thing of all," he says. The constant pain in his lower back makes running impossible. Sometimes, when the pain isn't under control, he can't get out of bed. Abrams has tried taking opioids. They help, but he feels he has to be careful because they're potentially addictive. He's also worried about building up a tolerance to them "I don't ever want to be in a situation where I need surgery and need to recover and opioid medication no longer does what it needs to do," he explains. The Food and Drug Administration approved a new non-opioid drug earlier this year called Journavx. It's a pill for severe acute pain that works by blocking plain signals from where someone hurts. It's offered hope for the 1 in 5 Americans who suffer from chronic pain, but it's also just out of reach. Journavx is the first new kind of painkiller in more than 20 years, and the medical community is cautiously optimistic that Journavx doesn't have the same addictive potential as opioids do. But the new pills are expensive, and not everyone has been able to access them, thanks to a narrowly-focused FDA approval and limited insurance coverage Abrams' doctor wanted him to be able to try Journavx. But the FDA only approved the medication for short-term use for acute pain, which is usually defined as lasting less than three months, such as right after surgery. Because Abrahm's pain is chronic, his insurance wouldn't cover it. A single Journavx pill costs around $15 without insurance, according to Vertex Pharmaceuticals, the drug's manufacturer. © 2025 npr

Keyword: Pain & Touch; Drug Abuse
Link ID: 29849 - Posted: 07.12.2025

Heidi Ledford Telltale features in standard brain images can reveal how quickly a person is ageing, a study of more than 50,000 brain scans has shown1. Pivotal features include the thickness of the cerebral cortex — a region that controls language and thinking — and the volume of grey matter that it contains. These and other characteristics can predict how quickly a person’s ability to think and remember will decline with age, as well as their risk of frailty, disease and death. Although it’s too soon to use the new results in the clinic, the test provides advantages over previously reported ‘clocks’ — typically based on blood tests — that purport to measure the pace of ageing, says Mahdi Moqri, a computational biologist who studies ageing at Harvard Medical School in Boston, Massachusetts. “Imaging offers unique, direct insights into the brain’s structural ageing, providing information that blood-based or molecular biomarkers alone can’t capture,” says Moqri, who was not involved in the study. The results were published today in Nature Aging. Genetics, environment and disease all affect the speed of biological ageing. As a result, chronological age does not always reflect the pace at which time takes its toll on the body. Researchers have been racing to develop measures to fill that gap. Ageing clocks could be used early in life to assess an individual’s risk of age-related illness, when it might still be possible to intervene. They could also aid testing of treatments aimed at slowing ageing, by providing a marker to track the effects of the intervention in real time. © 2025 Springer Nature Limited

Keyword: Development of the Brain; Brain imaging
Link ID: 29848 - Posted: 07.02.2025

By Mohana Ravindranath A new analysis of data gathered from a small Indigenous population in the Bolivian Amazon suggests some of our basic assumptions about the biological process of aging might be wrong. Inflammation is a natural immune response that protects the body from injury or infection. Scientists have long believed that long-term, low-grade inflammation — also known as “inflammaging” — is a universal hallmark of getting older. But this new data raises the question of whether inflammation is directly linked to aging at all, or if it’s linked to a person’s lifestyle or environment instead. The study, which was published today, found that people in two nonindustrialized areas experienced a different kind of inflammation throughout their lives than more urban people — likely tied to infections from bacteria, viruses and parasites rather than the precursors of chronic disease. Their inflammation also didn’t appear to increase with age. Scientists compared inflammation signals in existing data sets from four distinct populations in Italy, Singapore, Bolivia and Malaysia; because they didn’t collect the blood samples directly, they couldn’t make exact apples-to-apples comparisons. But if validated in larger studies, the findings could suggest that diet, lifestyle and environment influence inflammation more than aging itself, said Alan Cohen, an author of the paper and an associate professor of environmental health sciences at Columbia University. “Inflammaging may not be a direct product of aging, but rather a response to industrialized conditions,” he said, adding that this was a warning to experts like him that they might be overestimating its pervasiveness globally. “How we understand inflammation and aging health is based almost entirely on research in high-income countries like the U.S.,” said Thomas McDade, a biological anthropologist at Northwestern University. But a broader look shows that there’s much more global variation in aging than scientists previously thought, he added. © 2025 The New York Times Company

Keyword: Development of the Brain; Neuroimmunology
Link ID: 29847 - Posted: 07.02.2025

By Laura Sanders GLP-1 drugs may possess a new power: Easing migraines. In a small, preliminary study, a GLP-1 drug nearly halved the number of days people spent with a migraine in a given month. The results, presented June 21 at the European Academy of Neurology Congress in Helsinki, Finland, expand the possible benefits of the powerful new class of obesity and diabetes drugs. These pernicious, debilitating headaches are estimated to affect one billion people worldwide. Earlier studies have shown that GLP-1 agonists can reduce the pressure inside the skull, a squeeze that’s been implicated in migraines. Neurologist Simone Braca of the University of Naples Federico II in Italy and his colleagues explored whether liraglutide, an older relative of Ozempic and Wegovy, might help migraine sufferers. Thirty-one adults, 26 of them women, got daily injections of liraglutide for 12 weeks. These adults all had obesity and continued to take their current migraine medicines too. At the start of the experiment, participants had headaches on about 20 days out of a month. After 12 weeks of liraglutide, the average number dropped to about 11 days. “Basically, we observed that patients saw their days with headache halved, which is huge,” Braca says. Participants’ weight stayed about the same during the trial, suggesting that headache reductions weren’t tied to weight loss. If the results hold up in larger studies, they may point to treatments for migraine sufferers who aren’t helped by existing drugs. The results may also lead to a deeper understanding of the role of pressure inside the head in migraines, Braca says. © Society for Science & the Public 2000–2025.

Keyword: Obesity; Pain & Touch
Link ID: 29846 - Posted: 07.02.2025

By Claudia López Lloreda When it comes to cognition and behavior, neurons usually take center stage. They famously drive everything from thoughts to movements by way of synaptic communication, with the help of neuromodulators such as dopamine, norepinephrine and certain immune molecules that regulate neuronal activity and plasticity. But astrocytes play essential roles in these processes behind the scenes, according to four independent studies published in the past two months. Rather than acting solely on neurons, neuromodulators also act on astrocytes to influence neuronal function and behavior—making astrocytes crucial intermediates in activities previously attributed to direct communication between neurons, the studies suggest. For instance, norepinephrine sensitizes astrocytes to neurotransmitters and prompts them to regulate circuit computations, synapse function and various behaviors across diverse animal models, three of the studies—all published last month in Science—show. “Do neurons actually signal through astrocytes in a meaningful way during normal behavior or normal circuit function?” asks Marc Freeman, senior scientist at Oregon Health & Science University and principal investigator on one of the Science studies. These new findings “argue very strongly the answer is yes.” Astrocytes can also detect peripheral inflammation and modify the neurons that drive a stress-induced fear behavior in mice, according to the fourth study, published in April in Nature. Although astrocytes are no longer thought of as simply support cells, they were still “not really considered for having a real plasticity and a real important role,” says Caroline Menard, associate professor of psychiatry and neurosciences at the University of Laval, who was not involved in any of the new studies. Now “there’s more consideration from the field that behavior is not only driven by neurons, but there’s other cell types involved.” © 2025 Simons Foundation

Keyword: Glia; Learning & Memory
Link ID: 29845 - Posted: 07.02.2025

Humberto Basilio Mindia Wichert has taken part in plenty of brain experiments as a cognitive-neuroscience graduate student at the Humboldt University of Berlin, but none was as challenging as one he faced in 2023. Inside a stark white room, he stared at a flickering screen that flashed a different image every 10 seconds. His task was to determine what familiar object appeared in each image. But, at least at first, the images looked like nothing more than a jumble of black and white patches. “I’m very competitive with myself,” says Wichert. “I felt really frustrated.” Cognitive neuroscientist Maxi Becker, now at Duke University in Durham, North Carolina, chose the images in an attempt to spark a fleeting mental phenomenon that people often experience but can’t control or fully explain. Study participants puzzling out what is depicted in the images — known as Mooney images, after a researcher who published a set of them in the 1950s1 — can’t rely on analytical thinking. Instead, the answer must arrive all at once, like a flash of lightning in the dark (take Nature’s Mooney-images quiz below). Becker asked some of the participants to view the images while lying inside a functional magnetic resonance imaging (fMRI) scanner, so she could track tiny shifts in blood flow corresponding to brain activity. She hoped to determine which regions produce ‘aha!’ moments. Over the past two decades, scientists studying such moments of insight — also known as eureka moments — have used the tools of neuroscience to reveal which regions of the brain are active and how they interact when discovery strikes. They’ve refined the puzzles they use to trigger insight and the measurements they take, in an attempt to turn a self-reported, subjective experience into something that can be documented and rigorously studied. This foundational work has led to new questions, including why some people are more insightful than others, what mental states could encourage insight and how insight might boost memory. © 2025 Springer Nature Limited

Keyword: Attention; Learning & Memory
Link ID: 29844 - Posted: 06.28.2025

By Katrina Miller Take a look at this video of a waiting room. Do you see anything strange? Perhaps you saw the rug disappear, or the couch pillows transform, or a few ceiling panels evaporate. Or maybe you didn’t. In fact, dozens of objects change in this video, which won second place in the Best Illusion of the Year Contest in 2021. Voting for the latest version of the contest opened on Monday. Illusions “are the phenomena in which the physical reality is divorced from perception,” said Stephen Macknik, a neuroscientist at SUNY Downstate Health Sciences University in Brooklyn. He runs the contest with his colleague and spouse, Susana Martinez-Conde. By studying the disconnect between perception and reality, scientists can better understand which brain regions and processes help us interpret the world around us. The illusion above highlights change blindness, the brain’s failure to notice shifts in the environment, especially when they occur gradually. To some extent, all sensory experience is illusory, Dr. Martinez-Conde asserts. “We are always constructing a simulation of reality,” she said. “We don’t have direct access to that reality. We live inside the simulation that we create.” She and Dr. Macknik have run the illusion contest since 2005. What began as a public outreach event at an academic conference has since blossomed into an annual competition open to anyone in the world. They initially worried that people would run out of illusions to submit. “But that actually never happened,” Dr. Martinez-Conde said. “What ended up happening instead is that people started developing illusions, actually, with an eye to competing in the contest.” © 2025 The New York Times Company

Keyword: Vision; Attention
Link ID: 29843 - Posted: 06.28.2025

By Gordy Slack, MindSite News Lauren Kennedy West was still a teenager when she began to smell and hear things that weren’t there. Then to see things, too, that were invisible to others. Meanwhile, her moods began to intensify, sometimes turning very, very dark. “It was confusing, disturbing, and depressing,” she recalls. She had periods of elation, too. But when she came down from these, she’d keep descending until she hit emotional bottom. It got so bad that in her early 20s, at college, Kennedy West tried to end her life twice. Finally, when she was 25, she was diagnosed with schizoaffective disorder, a form of schizophrenia with powerful mood swings. The medications she was prescribed eased her worst symptoms, she said, but they also had troubling side effects that ranged from extreme weight gain and “dry mouth” to feeling lethargic and an episodic condition called oculogyric crisis which causes people to continually, involuntarily, gaze upward. Worst of all, she said, was the feeling of being “emotionally blunted.” Learning that she’d likely be taking those medications for the rest of her life was a blow, but the diagnosis gave Kennedy West a meaningful framework for her struggle. To be as stable, happy, and engaged as possible she would have to cultivate acceptance of her condition and the limitations it imposed, she was told. Driven by a hope that others might be spared the disabling confusion and depression she suffered before her diagnosis, Kennedy West and her partner started a YouTube Channel, which they called “Living Well with Mental Illness” (now “Living Well with Schizophrenia“) In frequent posts, Kennedy West recounted her own struggles and triumphs and interviewed experts on mental illness and related subjects. In early 2023, Christopher Palmer was a guest on the channel.

Keyword: Schizophrenia
Link ID: 29842 - Posted: 06.28.2025

By Sydney Wyatt The shape and density of dendritic spines fluctuate in step with the estrous cycle in the hippocampus of living mice, a new study shows. And these structural changes coincide with shifts in the stability of place fields encoded by place cells. “You can literally see these oscillations in hippocampal spines, and they keep time with the endocrine rhythms being produced by the ovaries,” says study investigator Emily Jacobs, associate professor of psychological and brain sciences at the University of California, Santa Barbara. She and her colleagues used calcium imaging and surgically implanted microperiscopes to view the dynamics of the dendritic spines in real time. The findings, published in Neuron in May, replicate and expand upon a series of cross-sectional studies of rat brain tissue in the early 1990s that documented sex hormone receptors in the hippocampus and showed that changes in estradiol levels across the estrous cycle track with differences in dendritic spine density. “The field of neuroendocrinology was really changed in the early ’90s because of this discovery,” Jacobs says. The new work is a “very important advancement,” says John Morrison, professor of neurology at the University of California, Davis, who was not involved in the research. It shows that spines change across the natural cycle of living mice, supporting estradiol’s role in this process, and it links these changes to electrophysiological differences, he says. “The most surprising part of this study is that everything seems to follow each other. Usually biology doesn’t cooperate like this,” Morrison says. Before the early 1990s, estrogens were viewed only as reproductive hormones, and their effects in the brain were thought to be limited to the hypothalamus, says Catherine Woolley, professor of neurobiology at Northwestern University, who worked on the classic rat hippocampus studies when she was a graduate student in the lab of the late Bruce McEwen. For that reason, her rat hippocampus results were initially met with “resistance,” she adds. A leader in the field once told her to “get some better advice” from her adviser “because estrogens are reproductive hormones, and they don’t have effects in the hippocampus,” she recalls. © 2025 Simons Foundation

Keyword: Hormones & Behavior; Learning & Memory
Link ID: 29841 - Posted: 06.28.2025